The Trump administration has fast-tracked research into psychedelics, and experts say it is likely a matter of time before the drugs are used to treat minors
The Trump administration has fast-tracked research into psychedelics, and experts say it is likely a matter of time before the drugs are used to treat minors, Trump signed the order on April 18.
The text of the order mentions federally banned psychedelics as promising options for the concerning number of Americans who are struggling with mental, behavioral and emotional disorders. And it points specifically to the roughly 6,000 military veterans who die by suicide every year. There is no mention of minors.
At least one company is already seeking U.S. Food and Drug Administration approval for a treatment involving psilocybin, the active compound in magic mushrooms, and the agency has also issued priority vouchers to companies investigating the compound’s effectiveness in treating depression. But if these drugs are ultimately approved for use in adults in the U.S., clinicians and pharmaceutical companies could, at some point, target them to people under the age of 18..
By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
“It’s inevitable, because once the drug gets approved, then you start moving down that age timeline and testing kids,” says Dominic Sisti, an associate professor of medical ethics and health policy at the University of Pennsylvania. The FDA requires more guardrails for drug trials in children than it does for those in adults. Psychoactive drug testing in kids garners even more ethical scrutiny; and because, which is still developing in children, these potential therapies would prompt more questions.
The history of medicine shows why: The discovery and synthesis of psychedelic drugs such as psilocybin and LSD prompted a flurry of research into their possible therapeutic benefits. That included controversial experiments such as the infamous and illegal CIA-led MKUltra brainwashing program, in which participants were unknowingly given large doses of LSD.
That program ran from 1953 to 1973.who reportedly suffered from loss of bladder control and what one researcher described as “serious sexual conflicts” was given the drug; her doctor claimed that her conditions improved. And in a 1963, researchers gave LSD to nonverbal autistic children. Some displayed a reduction in aggressive behaviors, while others became more violent, engaging in actions such as pushing, biting and pinching other children. These behaviors were seen as an improvement.
Doctors gave other kids LSD in bids to treat conditions such as schizophrenia—the efforts were largely inconclusive. The results of these early experiments were mixed, and ultimately, psychedelic research in children ended in 1970, when President Richard Nixon signed the Controlled Substances Act into law. It banned the use of many hallucinogenic drugs across the U.S. and slowed research into potential therapeutic uses, in adults and children, to a crawl for generations.
, driven in part by pop culture figures such as Rogan . Some scientists are optimistic about the possibilities, but others temper that enthusiasm because of the thorny ethical issues that come from the fact that many of these compounds can drastically change a person’s behavior and neurological makeup.
All courses of treatment in medicine generally require informed consent, in which a patient is made fully aware of the implications of a drug or procedure, both good and bad, says Robert Klitzman, a professor of psychiatry and co-founder of Columbia University’s Center for Bioethics. Whereas adults can make those decisions for themselves, the same isn’t true for children, especially younger ones, he adds.
And the effects of psychedelic drugs can be more powerful and longer-lasting on a developing brain than other psychoactive medications such as antidepressants, Klitzman adds.
“A lot of drugs have different effects in children than in adults, and that is because the adult brain is presumably already developed, whereas a child's brain is still developing,” he says. “So if you put various chemicals in a child’s brain while it’s still figuring out the world, so to speak, it can have additional risks that wouldn't appear in an adult.
” For example, LSD can cause what Klitzman called “depersonalization,” where the user experiences a feeling of disconnection from their mind or body, or both. This can fundamentally In some patients, that disconnect might be the desired outcome, particularly if a person is suffering from a personality disorder, notes the University of Pennsylvania’s Sisti.
But accurately diagnosing such disorders in children is difficult, and any attempt to use such drugs on them would require a careful, individualized analysis of the costs and benefits.
“I think it could alter the trajectory of a kid’s values in ways that are kind of unanticipated by parents and make parenting more complicated,” Sisti says. “I think that’s probably a good thing sometimes, but it could also be really disruptive to a family system. ” With those considerations in mind, some researchers are slowly beginning to explore the potential of psychedelics for treating minors. Acan treat anorexia nervosa.
The study’s leader, David Sjöström, a doctoral student at Lund University, says the severity of the negative outcomes associated with the disorder can outweigh any of the negatives associated with the drug.
“I think it needs to be weighed against the concerns about not doing the trial, because that also has a high risk of personality and cognitive ability changes but in a negative way if the anorexia nervosa is not treated,” he says. “We need to do robust clinical studies to get actual information on if there is an age-dependent difference between a 16- and 17-year-old and a 25- and a 30-year-old.
” Lund and his team are actively filtering out potential participants who are considered to be at high risk of side effects, such as those with a history of psychotic episodes or at high risk of suicide. In Sweden, a 16-year-old can give consent for medical treatment, though this study requires both parents or caregivers, as well as the child, to sign off on the latter’s participation as an extra precaution.
The trial also passed an independent safety review before it got the green light. Additionally, the use of the drug will be closely monitored, and all doses will be administered in the presence of two therapists. Even with these sorts of safety measures in place, Klitzman notes that there is an inherent limitation in how such studies can be conducted. Specifically, it isn’t feasible to create a control group that would be given a placebo.
“It turns out it’s basically impossible to blind , because people will know very quickly if they’ve had a hallucinogenic experience or not,” he says. “If you control a hallucinogen versus Prozac and other SSRI standard antidepressants, people immediately know which they’re on. ” Those limitations have forced researchers to exercise caution when performing trials with psychedelics.
While there is reason to believe the drugs may have therapeutic use in at least some people, what’s less clear is if the Trump executive order will actually spur real discovery. Understanding whether psychedelics might help some kids living with conditions that are difficult to treat requires diligent science, but Sisti doubts that the order will enable any new well-controlled studies that wouldn’t have gone forward otherwise.
For his part, Klitzman is concerned that the executive order could “open the floodgates too soon. ” Conventional antidepressants have a high success rate in adolescents, he notes, and with many outstanding questions about the long-term effects of psychedelic-based therapies, a slow and cautious approach to potential use among young people is needed.
“I would hope that decisions about ... how these drugs are would be based on evidence,” Klitzman says. “Could there be benefits? Yes. Do I have concerns?
Yes, because it is going to mean lots of people taking these drugs when there are other drugs that can help them more, and there may be some risks involved. ”has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.
, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized. There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.
Please follow us on Google to support us United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Trump administration says it will comply with court order to pause $1.8 billion compensation fundThe Trump administration says it will comply with a court ruling temporarily blocking a nearly $1.8 billion fund meant to compensate allies of President Donald Trump.
Read more »
Trump administration says it will comply with court order to pause $1.8 billion compensation fundWASHINGTON (AP) — The Trump administration said Monday it will comply with a court ruling temporarily blocking a nearly $1.8 billion fund meant to compensate
Read more »
Trump reportedly called Netanyahu 'f***ing crazy' before announcing halt to Israel-Hezbollah fightingFormer President Donald Trump berated Israeli Prime Minister Benjamin Netanyahu during a tense phone call, calling him 'f***ing crazy' and saying he'd be in prison without Trump's support. The call preceded Trump's announcement on Truth Social that Israel had halted a planned major raid on Lebanon and that fighting between Israel and Hezbollah had stopped. Trump expressed skepticism about the ceasefire's durability. Meanwhile, Iran reportedly halted communications with the US through Pakistani intermediaries, vowing to block the Strait of Hormuz and demanding Israel's full withdrawal from Lebanon and Gaza.
Read more »
US President Donald Trump and Israeli Prime Minister Benjamin Netanyahu in fiery phone call over Lebanon conflictUS President Donald Trump and Israeli Prime Minister Benjamin Netanyahu had a tense phone call over the escalating conflict in Lebanon, with Trump reportedly telling Netanyahu that he was 'f***ing crazy' and that 'everybody hates Israel'. The call came just before Trump announced on Truth Social that the Israeli prime minister 'turned his troops around' instead of conducting a 'major raid' on Lebanon. Netanyahu later cast doubt on Trump's claim of a ceasefire, saying that his country would strike Beirut if Hezbollah doesn't stop attacking Israel.
Read more »